Many of our leaders have worked together for more than 210 dog years, at some of the world’s largest pharmaceutical companies.
During those years we learned some important lessons the hard way. Like how important it is to match new products with true needs in the marketplace. And that making large investments before early stage clinical evaluation is a sure-fire way to end up in the doghouse.*
Today we know how to keep the process, and products, moving at the speed of a hyped-up puppy.
Our team has developed, launched, or marketed more than 20 companion animal products in the veterinary industry for dogs, cats, and horses.
Many of these products—like HEARTGARD® (ivermectin), FRONTLINE®, SENTINEL® (milbemycinoxime/lufenuron), DERAMAXX® (deracoxib) and PERCORTEN-V® (DOCP)—became category top-sellers. Today that list of canine and feline products represents approximately 25% of total revenue in the US small animal veterinary segment.*
You’ll purr when you see the list of key milestones in the veterinary industry we’ve been a part of. We have more firsts than a cat has lives. To learn more click here.
If you want a proven track record, we have it in spades.
FRONTLINE and HEARTGARD are registered trademarks of Merial.
DERAMAXX and PERCORTEN-V are registered trademarks of Elanco.
SENTINEL is a registered trademark of Virbac.
It’s not enough to rest on laurels. That’s why we have been issued 44 patents, and have an additional 67 pending worldwide. In fact, we’ve introduced innovations across almost the entire spectrum of companion animal medicine—and touched nearly every product and treatment category.
Our entire team is constantly evaluating the marketplace for opportunities to fulfill unmet needs, even ones that pet owners and veterinarians don’t realize they have.
Our patented, tasty formulations offer superior ease of use for pet owners, which means those pets are actually getting the medications they need. Easy treatments. Healthy pets. Happy owners. Popular products. It’s a formula that works.
Understanding why people love their companion animals is easy. Getting new or improved FDA-pharmaceuticals to market is not.
At Piedmont Animal Health we know a thing or two about streamlining the process, so nobody is stuck chasing their tail. In fact, we’ve been known to get products to market nearly 40% faster than the average time.*
Using human resource efficiencies—and hiring only the best team members—means we can remain an incredibly sleek organization, helping us stay flexible, so we can quickly adjust to changing market trends.
Piedmont Animal Health currently has more than 20 products in various stages of development, one of which received FDA approval in January 2015, and two more expected to receive approval by the end of 2015.
We plan to commercialize over 10 of these products in our current portfolio, and hold out-licensing agreements with major global pharmaceutical companies for the remaining products.
Based on independent market research*, sales of our retained portfolio products are projected to reach $175 million annually by the end of 2020.